LWAM
CDTX

Legacy Wealth Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Legacy Wealth Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,500
Closed -$27.6K – 341
2024
Q1 		$27.6K Hold
1,500
– – 0.01% 342
2023
Q4 		$23.8K Hold
1,500
– – 0.01% 336
2023
Q3 		$28.3K Hold
1,500
– – 0.01% 331
2023
Q2 		$33.9K Buy
+1,500
New +$35.3K 0.01% 335

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Legacy Wealth Asset Management's CDTX Position: Q2 2024 in Review

Legacy Wealth Asset Management sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 1,500 shares — an estimated $27.6K sold.

Legacy Wealth Asset Management first reported a position in CDTX in Q2 2023 and held it in 4 quarters. The position peaked at $33.9K in Q2 2023. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • Legacy Wealth Asset Management reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Legacy Wealth Asset Management sold 1,500 Cidara Therapeutics shares in Q2 2024, an estimated $27.6K.
  • Legacy Wealth Asset Management first reported a position in Cidara Therapeutics in Q2 2023 and held it in 4 quarters.
  • Legacy Wealth Asset Management's Cidara Therapeutics position peaked at $33.9K in Q2 2023.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on Legacy Wealth Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.